OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY

Topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keywords: Monoclonal antibody, Multiple myeloma, Survival


1 University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France
2 Department of Hematology, Mayo Clinic Rochester, Rochester, MN, United States
3 Vejle Hospital and University of Southern Denmark, Vejle, Denmark
4 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
5 Hematology, University Hospital Hôtel-Dieu, Nantes, France
6 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
7 Royal Wolverhampton NHS Trust and University of Wolverhampton, Wolverhampton, United Kingdom
8 Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden
9 Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
10 University of Melbourne, St Vincent’s Hospital, Melbourne, Australia
11 University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany
12 Department of Medicine/Haematology, NUI, Galway, Ireland
13 CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France
14 Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
15 Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
16 Florida Cancer Specialists, St. Petersburg, FL, United States
17 Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, United States
18 CHD Vendée, La Roche sur Yon, France
19 Centre Hospitalier Universitaire (CHU) de Caen, Caen, France
20 Department of Clinical Haematology, Hospital Necker-Enfants Malades, Paris, France
21 CHU Poitiers, Hôpital la Milétrie, Poitiers, France
22 Genmab US, Inc., Plainsboro, NJ, United States
23 Janssen Research & Development, LLC, Raritan, NJ, United States
24 Janssen Research & Development, Beerse, Belgium
25 Janssen Research & Development, LLC, Spring House, PA, United States
26 Janssen Research & Development, LLC, Leiden, Netherlands
27 Levine Cancer Institute/Atrium Health, Charlotte, NC, United States

Background: The primary analyses of the phase 3 ALCYONE, MAIA, and CASSIOPEIA studies established the superior clinical efficacy of daratumumab (DARA) in combination with standard-of-care regimens versus standard of care alone for patients with newly diagnosed multiple myeloma (NDMM). In ALCYONE, after longer follow-up, an overall survival (OS) benefit was observed; adding DARA to bortezomib, melphalan, and prednisone significantly reduced the risk of death by 40%. In the primary analysis of MAIA, DARA plus lenalidomide and dexamethasone (D-
Rd) reduced the risk of disease progression or death by 44% versus lenalidomide and dexamethasone (Rd).

**Aims:** To report the updated efficacy and safety of D-Rd versus Rd after almost 5 years of median follow-up in transplant-ineligible patients with NDMM from the prespecified interim OS analysis of MAIA (NCT02252172).

**Methods:** Patients with NDMM ineligible for high-dose chemotherapy and autologous stem cell transplantation due to age ≥65 years or comorbidities were randomized 1:1 to D-Rd or Rd. All patients received 28-day cycles of Rd (R: 25 mg orally once daily on Days 1-21; d: 40 mg orally on Days 1, 8, 15 and 22) with or without DARA (16 mg/kg intravenously once weekly for Cycles 1-2, once every 2 weeks for Cycles 3-6, and once every 4 weeks thereafter). In both arms, patients were treated until disease progression or unacceptable safety events. The primary endpoint was progression-free survival (PFS). Key secondary endpoints included overall response rate (ORR), OS, and safety.

**Results:** 737 patients (D-Rd, 368; Rd, 369) were enrolled in this study. Baseline characteristics were well balanced between arms. The median age was 73 (range, 45-90) years. After a median follow-up of almost 5 years (56.2 months), a significant 32% reduction in the risk of death was observed with D-Rd versus Rd; median OS was not reached (NR) in either arm (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.53-0.86; P=0.0013 [crossing the prespecified stopping boundary of P=0.0414]). The estimated 5-year OS rate was 66.3% with D-Rd and 53.1% with Rd (Figure A). The updated median PFS was NR with D-Rd versus 34.4 months with Rd (HR, 0.53; 95% CI, 0.43-0.66; P<0.0001; Figure B). The estimated 5-year PFS rate was 52.5% with D-Rd and 28.7% with Rd. The updated ORR was 92.9% with D-Rd versus 81.6% with Rd (P<0.0001). No new safety signals were identified with longer follow-up. The most common (in >15% of patients in either arm) grade 3/4 treatment-emergent adverse events for the D-Rd/Rd arms were neutropenia (54.1%/37.0%, respectively), pneumonia (19.2%/10.7%), anemia (16.8%/21.6%), and lymphopenia (16.5%/11.2%).

**Summary/Conclusion:** After almost 5 years of follow-up, a significant and clinically meaningful OS improvement was demonstrated with the use of D-Rd versus Rd in patients with NDMM who are transplant ineligible, representing a 32% reduction in the risk of death. The significant PFS benefit of D-Rd versus Rd from the primary analysis (median follow-up, 28 months) was maintained, with a 47% reduction in risk of disease progression or death and a median PFS for D-Rd NR. The favorable benefit-risk profile observed supports the use of D-Rd in transplant-ineligible patients with NDMM. These results, together with the OS benefit observed in ALCYONE, support the use of frontline DARA-based combination regimens to maximize PFS for optimal long-term outcomes.